Ive even tried Botox and I went as far as I was looking into treatment during surgery which I found to be very risky for myself with not very many good outcomes, and with the hyperhidrosis, it is a very embarrassing condition
Dual GIP/GLP-1 agonists now represent the highest-revenue growth segment in the GLP-1 weight loss drug market at 18.4% CAGR , with tirzepatide generating USD 18.3 billion in 2025 revenue through Zepbound and Mounjaro surpassing Eli Lillys entire insulin franchise within two years of commercial launch
10.1038/s41598-017-13368-2 246 KnigR
Not only did you treat us you took the time to sit, talk and listen to our concerns
The Ozempic prescribing information names fatigue, along with dysgeusia and dizziness, among adverse reactions occurring at a frequency greater than 0.4% meaning it is documented but uncommon relative to the reactions that dominate this drug's profile
When people think they can only lose weight from their belly, they often look for quick fixes